SELETRACETAM

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H14F2N2O2
Molecular Weight	232.2272
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC[C@H](N1C[C@@H](CC1=O)C=C(F)F)C(N)=O

InChI

InChIKey=ANWPENAPCIFDSZ-RQJHMYQMSA-N

InChI=1S/C10H14F2N2O2/c1-2-7(10(13)16)14-5-6(3-8(11)12)4-9(14)15/h3,6-7H,2,4-5H2,1H3,(H2,13,16)/t6-,7+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C10H14F2N2O2
Molecular Weight	232.2272
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19055493 | https://www.ncbi.nlm.nih.gov/pubmed/17199025 | https://www.ncbi.nlm.nih.gov/pubmed/18183537

Seletracetam, a pyrrolidone derivative is a new drug in epilepsy development. Seletracetam has high binding affinity to the synaptic vesicle 2A (SV2A) protein. In addition, was discovered, that the drug bound to N-type calcium channels and inhibited high-voltage-activated Ca2+ currents and intracellular Ca2+ increase. Seletracetam participated in Phase III clinical trials; however, all these studies for the treatment of epilepsy were terminated. Moreover, it is unknown whether planned phase IIb/III trials will begin.

Originator

Approval Year

PubMed

Title	Date	PubMed
Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.	2010-02-12	20166767
Discovery of indolone acetamides as novel SV2A ligands with improved potency toward seizure suppression.	2010-02-01	20039359
Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy.	2009-07-01	19383493
Seletracetam (ucb 44212) inhibits high-voltage-activated Ca2+ currents and intracellular Ca2+ increase in rat cortical neurons in vitro.	2009-04	19055493
Brivaracetam and seletracetam, two new SV2A ligands, improve paroxysmal dystonia in the dt sz mutant hamster.	2008-12-28	19014930
Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions.	2008-03-02	19443931
Modifications of antiepileptic drugs for improved tolerability and efficacy.	2008-02-14	19787095
Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.	2008-01	18183537
The effectiveness of anticonvulsants in psychiatric disorders.	2008	18472486
Seletracetam (UCB 44212).	2007-01	17199025
Progress report on new antiepileptic drugs: a summary of the Eigth Eilat Conference (EILAT VIII).	2007-01	17158031
New antiepileptic drugs that are second generation to existing antiepileptic drugs.	2006-06	16732716
Diverse mechanisms of antiepileptic drugs in the development pipeline.	2006-06	16621450
Drugs in development for Parkinson's disease: an update.	2006-01	16425668
Antiepileptic drug discovery: lessons from the past and future challenges.	2005	16238713

Patents

Sample Use Guides

In Vivo Use Guide

Ucb 44212 (Seletracetam) Used at Doses of 10, 20, 40, and 80 mg b.i.d. (Total Daily Doses of 20 - 160 mg) Administration (Oral Capsules) in Adult Subjects (18 - 65 Years)

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:59:26 GMT 2025` Edited by `admin` on `Mon Mar 31 17:59:26 GMT 2025`
Record UNII	RFR2CH3QZK
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SELETRACETAM

Official Name

English

UCB 44212

Preferred Name

English

seletracetam [INN]

Common Name

English

SELETRACETAM [USAN]

Common Name

English

UCB-44212

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C264